

Title (en)  
METHODS AND COMPOSITIONS FOR TREATING HYPERTENSION, ANGINA AND OTHER DISORDERS USING OPTICALLY PURE S(-) NITRENDIPINE.

Title (de)  
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HYPERTONIE, ANGINA UND ANDEREN ERKRANKUNGEN UNTER VERWENDUNG VON OPTISCH REINEM S(-) NITRENDIPIN.

Title (fr)  
PROCEDES ET COMPOSITIONS PERMETTANT DE TRAITER L'HYPERTENSION, LES ANGINES ET D'AUTRES AFFECTIONS AU MOYEN DE NITRENDIPINE S(-) OPTIQUEMENT PURE.

Publication  
**EP 0663822 A4 19970423 (EN)**

Application  
**EP 93922832 A 19931005**

Priority  
• US 9309463 W 19931005  
• US 95720092 A 19921006

Abstract (en)  
[origin: WO9407476A1] Methods and compositions are disclosed utilizing the optically pure S(-) isomer of nitrendipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the administration of the racemic mixture of nitrendipine. The S(-) isomer of nitrendipine is also useful for the treatment of angina and such other conditions as may be related to the activity of S(-) nitrendipine as a calcium channel antagonist without the concomitant liability of adverse effects associated with the racemic mixture of nitrendipine.

IPC 1-7  
**A61K 31/04**

IPC 8 full level  
**A61K 9/08** (2006.01); **A61K 31/44** (2006.01); **A61P 9/00** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 11/08** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 25/00** (2006.01); **A61P 43/00** (2006.01); **C07D 211/90** (2006.01)

CPC (source: EP)  
**A61K 31/44** (2013.01); **A61P 9/00** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 11/08** (2017.12); **A61P 13/02** (2017.12); **A61P 15/00** (2017.12); **A61P 25/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)  
• [XD] ELTZE ET AL.: "Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-dihydropyridine Calcium Channel Antagonists", CHIRALITY, vol. 2, no. 4, 1990, pages 233 - 240, XP000616626  
• [X] MAST ET AL.: "Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.", BR. J. CLIN. PHARMAC., vol. 33, no. 1, 1992, pages 51 - 59, XP000617464  
• [X] STRIESSNIG ET AL.: "Human red-blood-cell Ca<sup>2+</sup>-antagonist binding sites", EUR. J. BIOCHEM., vol. 150, no. 1, 1985, pages 67 - 77, XP000616619  
• [A] HOELTJE ET AL.: "Qualitative and Quantitative Structure-Activity Relationship for Calcium Channel Modulating 1,4-Dihydropyridine Derivatives: A Hypothetical Molecular Receptor Model", QUANT. STRUCT. ACT. RELAT., vol. 7, no. 3, 1988, pages 174 - 178, XP000616609  
• [X] PATENT ABSTRACTS OF JAPAN vol. 015, no. 252 (C - 0844) 26 June 1991 (1991-06-26)  
• See references of WO 9407476A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9407476 A1 19940414**; AU 5170393 A 19940426; CA 2146545 A1 19940414; EP 0663822 A1 19950726; EP 0663822 A4 19970423; JP H08502263 A 19960312

DOCDB simple family (application)  
**US 9309463 W 19931005**; AU 5170393 A 19931005; CA 2146545 A 19931005; EP 93922832 A 19931005; JP 50938394 A 19931005